First patient receives Inovio's universal HIV vaccine
The purpose of the trial is to determine the tolerability and safety of the vaccine. Part of a partnership between Inovio and the HIV Vaccine Trials Network (HVTN), the trial is being funded by the National Institute of Allergy and Infectious Diseases (NIAID).
Researchers will measure the responses of the immune system after the patients receive the vaccine. The patients are separated into four groups. The various groups will receive the new vaccine with as well as without IL-12, an immune activator, all of which will be administered through the skin or muscle with the company’s CELLECTRA delivery technology.
"This latest HIV vaccine trial will allow us to test our universal HIV vaccine, with the potential to provide protection against viruses from all major global clades,” Dr. J. Joseph Kim, president and CEO of Inovio, said. “This is a major step forward in extending our clinical experience with the PENNVAX platform and the innovation developed from our previous PENNVAX human trials. We are confident that the results of this trial will advance our previous findings that demonstrated best-in-class cellular immune responses. Inovio looks forward to continuing our long-standing and fruitful collaborations with both NIAID and HVTN."